Navigation Links
First Subjects Dosed in Phase 1 Clinical Study of NKTR-171, A New Peripherally-Restricted Sodium Channel Blocker to Treat Neuropathic Pain
Date:1/14/2014

lerable for many patients.  A peripherally-restricted sodium channel blocker with good efficacy and low CNS side effects would be an important advance in the treatment of patients with debilitating neuropathic pain."

About NKTR-171In preclinical studies, NKTR-171 demonstrated an improved efficacy and CNS side effect profile when compared to pregabalin (Lyrica®), the most highly prescribed therapy in the treatment of neuropathic pain. 2,3
NKTR-171 also exhibited significantly reduced CNS penetration versus currently-approved sodium channel blockers.2  NKTR-171 did not significantly impair motor coordination at doses demonstrating analgesia, suggesting that the therapeutic index, or the ability to provide analgesia at doses that do not cause significant CNS side effects, may be greater for NKTR-171 than for currently available therapies.2,3 In pre-clinical in vitro data, NKTR-171 was shown to produce frequency-dependent blockade of inactivated sodium channels, meaning NKTR-171 preferentially blocks the abnormal, rapidly-firing neurons associated with neuropathic pain and spares normal nerve function in unaffected tissues.2,3About Neuropathic PainNeuropathic pain, also known as nerve pain or peripheral neuropathy, is the result of nerve damage and can be caused by such diverse conditions as diabetes, shingles, cancer, HIV, multiple sclerosis and fibromyalgia, as well as injury or trauma to the nerves.  According to the Neuropathy Association, an estimated 1 in 15 Americans suffer from peripheral neuropathy4.  Its prevalence is particularly high among diabetes patients and incidence increases with age4.  Though neuropathic pain is a very common condition, the symptoms of it can be highly variable, including numbness, tingling, and pricking sensations, sensitivity to touch, or burning sensations, making diagnosis difficult.  If left untreated, peripheral
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Avanir Pharmaceuticals Pre-announces Preliminary Fiscal 2014 First Quarter Financial Information
2. 2014 Beauty Breakthrough -- Age-Defying Laser brings professional, anti-aging treatments into the home for the first time
3. QIAGEN and Exosome Diagnostics to Develop First-In-Class, Non-Invasive Diagnostics for Key Genetic Biomarkers in Lung and Other Cancers
4. Hill-Rom Holdings, Inc. Hosts Fiscal 2014 First Quarter Earnings Conference Call and Webcast
5. Xlumena Announces Initial Commercial Use of its First-in-Class AXIOS Stent and Delivery System for Treatment of Pancreatic Pseudocysts and Fluid Collections
6. Hologic to Release First Quarter Fiscal 2014 Operating Results on Monday, February 3, 2014
7. Philips receives FDA clearance for First-Ever Spectral Breast Density Measurement Application
8. Harrisburg-based Cardiovascular Institute Performs First MitraClip Procedure in Pennsylvania
9. Caris Life Sciences Receives Tumor Profiling Industrys First ISO 15189 Medical Laboratory Accreditation
10. According to Surveyed U.S. Oncologists, Perjeta is Prescribed to Over One-Third of First-Line Advanced/Metastatic HER2-Positive, HR-Negative Breast Cancer Patients
11. Lilly Declares First-Quarter 2014 Dividend
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... 23, 2014  SI-BONE, Inc., a medical device company ... ® a minimally invasive surgical (MIS) device indicated ... that the U.S. Patent and Trademark Office has awarded ... for the fixation and fusion of bone.  This newly ... tapered distal end that may be placed from one bone across ...
(Date:9/23/2014)... Sept. 23, 2014 Report Details ... you trends, R&D and predicted revenues Do you ... Now get the latest analysis for those cancer ... opportunities and revenue forecasts. Visiongain,s new report ... kinase inhibition and related technology. There avoid missing ...
(Date:9/23/2014)... , Sept. 23, 2014 EnzymeBioSystems (OTCBB: ... along with the process of evaluating an enzyme ... in fighting tumors. In an effort to evaluate this ... with various contract research organizations to enlist their ... the use of an antitumor natural product called ...
Breaking Medicine Technology:SI-BONE, Inc. Strengthens Patent Portfolio with the U.S. Patent and Trademark Office's Issuance of Threaded, Fenestrated Implant Method Patent 2SI-BONE, Inc. Strengthens Patent Portfolio with the U.S. Patent and Trademark Office's Issuance of Threaded, Fenestrated Implant Method Patent 3Kinase Inhibitors for Treating Cancer: Industry Analysis, R&D Trends and World Market Forecasts 2014-2024 2Kinase Inhibitors for Treating Cancer: Industry Analysis, R&D Trends and World Market Forecasts 2014-2024 3Kinase Inhibitors for Treating Cancer: Industry Analysis, R&D Trends and World Market Forecasts 2014-2024 4Kinase Inhibitors for Treating Cancer: Industry Analysis, R&D Trends and World Market Forecasts 2014-2024 5EnzymeBioSystems Announces Progress with an Enzyme Compound 2
... today reported financial results for the third quarter ended,September ... Novavax reported a net loss of $9.0 million, or ... $5.0 million net loss, or the,equivalent of $0.08 loss ... For the nine months ended September 30, 2007, the ...
... Allos,Therapeutics, Inc. (Nasdaq: ALTH ) today announced ... non-randomized, open-label, multi-center dose,escalation study of the Company,s ... tumors or non-Hodgkin,s lymphoma (NHL). "We are ... said Pablo,J. Cagnoni, M.D., Chief Medical Officer of ...
Cached Medicine Technology:Novavax Reports Third Quarter 2007 Financial Results and Progress with Vaccine Development Programs 2Novavax Reports Third Quarter 2007 Financial Results and Progress with Vaccine Development Programs 3Novavax Reports Third Quarter 2007 Financial Results and Progress with Vaccine Development Programs 4Novavax Reports Third Quarter 2007 Financial Results and Progress with Vaccine Development Programs 5Novavax Reports Third Quarter 2007 Financial Results and Progress with Vaccine Development Programs 6Allos Therapeutics Initiates Study of RH1 in Patients with Advanced Solid Tumors or non-Hodgkin's Lymphoma 2Allos Therapeutics Initiates Study of RH1 in Patients with Advanced Solid Tumors or non-Hodgkin's Lymphoma 3Allos Therapeutics Initiates Study of RH1 in Patients with Advanced Solid Tumors or non-Hodgkin's Lymphoma 4
(Date:9/23/2014)... The inaugural single day event in ... New Otani Tokyo Gardens in Tokyo. Clinical data scientists will ... validation. , The second single day event in China ... in Shanghai. The clinical data scientists attending this event will ... and listings, which display data collected in clinical studies and ...
(Date:9/23/2014)... (PRWEB) September 23, 2014 "The primary purpose ... control," said an inventor from Sacramento, Ca.. "Call lights are ... or left hanging on the IV pole out of the ... the nurse call device whenever they need it, I created ... effectively position the nurse call device within easy reach. The ...
(Date:9/23/2014)... 2014 From first-hand experience, Matthew O'Farrell ... and how it can be treated. , A medically ... in 2006. His platoon sustained multiple attacks resulting in ... diagnosed with combat-related PTSD and honorably discharged from the ... I had distanced myself from my friends and family,” ...
(Date:9/23/2014)... HealthDay Reporter TUESDAY, Sept. 23, 2014 (HealthDay ... providing better care, not more care, ... A new report suggests that,s the direction the ... IMS Institute for Healthcare Informatics in Parsippany, N.J., identifies 10 ... delivery of health care and use of medicines over the ...
(Date:9/23/2014)... What information do patients need ... Forum (NQF) released a report ( http://bit.ly/1DwekE9 ), ... infographic ( http://bit.ly/1tX3lzA ) resulting from an in-depth ... patients define affordability, and what information and changes ... possible healthcare at the lowest possible cost. ...
Breaking Medicine News(10 mins):Health News:PhUSE Further Expands its Global Community Into the Asian Region 2Health News:Virtual Reality software to help treat PTSD 2Health News:Virtual Reality software to help treat PTSD 3Health News:Report Identifies Game Changers for U.S. Health Care 2Health News:Report Identifies Game Changers for U.S. Health Care 3Health News:Finding Affordable Care: Asking the Right Question is Key 2
... consumption dropped, study found , FRIDAY, June 18 (HealthDay ... may reduce consumption and help lower levels of obesity ... suggests. , Researchers examined what happened during a time ... in Boston increased the price of regular soft drinks ...
... , ... Life sell an extensive range of vitamins supplements and nutritional supplements by top manufacturers ... ... Established in 1999, Vitamins for Life (vitaminsforlife.co.uk) supplies practitioner-grade nutritional supplements that ...
... 2010: Systemic Lupus Erythematosus (SLE) patients from Brazil ... that their rheumatic conditions negatively affect their emotional ... today at EULAR 2010, the Annual Congress of ... Furthermore, findings of the French study specifically revealed ...
... The effects of Systemic Lupus Erythematosus (SLE) may differ ... results of a new study presented today at EULAR ... Rheumatism in Rome, Italy. In particular, the study reinforced ... European subpopulations. Results from a Europe-wide study, involving ...
... Kids Bento ... , ... 18, 2010 -- School’s about to start and so is the mad morning scramble of ... kids’ bento boxes , from Laptop Lunches. They’re ideal for packing fun, wholesome, ...
... ... 360 Degree Guarantee and provide consumers with coverage that extends past the original manufacturer labor ... standard warranty. , ... 18, 2010 -- Treadmill Doctor has announced the introduction of their new 360 ...
Cached Medicine News:Health News:People May Skip Soft Drinks Rather Than Pay More 2Health News:Natural Health Online Retailer VitaminsForLife.co.uk Expands Inventory to Meet UK Demands 2Health News:Natural Health Online Retailer VitaminsForLife.co.uk Expands Inventory to Meet UK Demands 3Health News:Sex lives of patients are negatively affected by rheumatoid arthritis and SLE 2Health News:Sex lives of patients are negatively affected by rheumatoid arthritis and SLE 3Health News:Kids' Lunchboxes Go Bento for Easy Back to School Lunch Making, Thanks to Laptop Lunches 2Health News:Treadmill Doctor 360 Degree Guarantee Extended Service Plans 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: